Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives $7.33 Consensus Target Price from Brokerages

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $7.3333.

WHWK has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 target price on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Citigroup initiated coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They set an “outperform” rating on the stock. Finally, Citizens Jmp started coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 target price on the stock.

Whitehawk Therapeutics Stock Performance

Shares of NASDAQ WHWK opened at $4.70 on Monday. The stock has a market capitalization of $232.42 million, a PE ratio of -2.80 and a beta of 0.70. The stock’s fifty day simple moving average is $3.88 and its two-hundred day simple moving average is $3.05. Whitehawk Therapeutics has a 12-month low of $1.57 and a 12-month high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. On average, equities analysts predict that Whitehawk Therapeutics will post -1.44 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Scott M. Giacobello sold 141,600 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $4.13, for a total transaction of $584,808.00. Following the completion of the sale, the chief financial officer owned 295,224 shares in the company, valued at approximately $1,219,275.12. This represents a 32.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David James Lennon sold 14,500 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $3.38, for a total value of $49,010.00. Following the sale, the chief executive officer owned 518,622 shares of the company’s stock, valued at approximately $1,752,942.36. This represents a 2.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 705,358 shares of company stock worth $2,584,564. Insiders own 49.90% of the company’s stock.

Institutional Trading of Whitehawk Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd purchased a new stake in shares of Whitehawk Therapeutics during the 4th quarter valued at $28,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Whitehawk Therapeutics during the 1st quarter valued at $40,000. ABG Innovation Capital Partners III GP Ltd purchased a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at $51,000. Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics in the 3rd quarter worth $84,000. Finally, Marshall Wace LLP purchased a new position in Whitehawk Therapeutics in the 4th quarter worth $164,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.